Soluble Tumor Necrosis Factor Receptor 1 Is Associated with Glomerular Filtration Rate Progression and Incidence of Chronic Kidney Disease in Two Community-Based Cohorts of Elderly Individuals

CardioRenal Medicine

Volumn 5, Issue 4, 2015, Pages 278-288

  Carlsson, Axel C ^a,b   Nordquist, Lina ^c   Larsson, Tobias E ^a   Carrero, Juan Jesús ^a   Larsson, Anders ^d   Lind, Lars ^e   Ärnlöv, Johan ^c,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f DALARNA UNIVERSITY   (Sweden)

Author keywords

Albumin creatinine ratio; Chronic kidney disease; Community; Glomerular filtration; Inflammation; TNF

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR 1;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 84945925649     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000435863     Document Type: Article

References (36)

1. Pass HI, Mew D, Pass HA, Temeck BK: The macrophage, TNF, and other cytokines. Chest Surg Clin N Am 1995; 5: 73-90.
2. Cabal-Hierro L, Lazo PS: Signal transduction by tumor necrosis factor receptors. Cell Signal 2012; 24: 1297-1305.
3. Carlsson AC, Juhlin CC, Larsson TE, Larsson A, Ingelsson E, Sundstrom J, Lind L, Arnlov J: Soluble tumor necrosis factor receptor 1 (sTNFR1) is associated with increased total mortality due to cancer and cardiovascular causes-findings from two community based cohorts of elderly. Atherosclerosis 2014; 237: 236-242.
4. Luna JM, Moon Y, Liu K, Spitalnik S, Paik M, Sacco R, Elkind MS: Tumour necrosis factor receptor 1 and mortality in a multi-ethnic cohort: The Northern Manhattan Study. Age Ageing 2013; 42: 385-390.
5. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS: Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23: 516-524.
6. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS: Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515.
7. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007-1012.
8. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G: Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care 2013; 36: 2317-2323.
9. Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH: Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 2014; 37: 226-234.
10. Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Arnlov J: Soluble TNF receptors and kidney dysfunction in the elderly. J Am Soc Nephrol 2014; 25: 1313-1320.
11. Keller C, Katz R, Cushman M, Fried LF, Shlipak M: Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008; 9: 9.
12. Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, Cummings SR, Harris TB, Shlipak MG: Kidney function and markers of inflammation in elderly persons without chronic kidney disease: The health, aging, and body composition study. Kidney Int 2007; 71: 239-244.
13. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O'Donnell CJ, Kathiresan S, Meigs JB, Keaney JF Jr, Rong J, Benjamin EJ, Fox CS: Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011; 26: 920-926.
14. Lind L, Fors N, Hall J, Marttala K, Stenborg A: A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005; 25: 2368-2375.
15. Helmersson J, Vessby B, Larsson A, Basu S: Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004; 109: 1729-1734.
16. Flodin M, Jonsson AS, Hansson LO, Danielsson LA, Larsson A: Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in ml/min/1.73 m 2 from the cystatin C values in mg/l. Scand J Clin Lab Invest 2007; 67: 560-567.
17. Larsson A, Malm J, Grubb A, Hansson LO: Calculation of glomerular filtration rate expressed in ml/min from plasma cystatin c values in mg/l. Scand J Clin Lab Invest 2004; 64: 25-30.
18. Wandell PE, Carlsson AC, de Faire U, Hellenius ML: Prevalence of blood lipid disturbances in Swedish and foreign-born 60-year-old men and women in Stockholm, Sweden. Nutr Metab Cardiovasc Dis 2011; 21: 173-181.
19. Miyazawa I, Araki S, Obata T, Yoshizaki T, Morino K, Kadota A, Ugi S, Kawai H, Uzu T, Nishio Y, Koya D, Haneda M, Kashiwagi A, Maegawa H: Association between serum soluble TNFα receptors and renal dysfunction in type 2 diabetic patients without proteinuria. Diabetes Res Clin Pract 2011; 92: 174-180.
20. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329.
21. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S: Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999; 277:F766-F772.
22. Navarro-Gonzalez JF, Mora-Fernandez C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
23. Al-Lamki RS, Wang J, Vandenabeele P, Bradley JA, Thiru S, Luo D, Min W, Pober JS, Bradley JR: TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005; 19: 1637-1645.
24. Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E: The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF-αR1: A comparison with infliximab treatment. Eur J Pharmacol 2013; 700: 134-146.
25. Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, Warram JH, Krolewski AS: Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009; 4: 62-70.
26. Friederich-Persson M, Thorn E, Hansell P, Nangaku M, Levin M, Palm F: Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension 2013; 62: 914-919.
27. Tanaka T, Kato H, Kojima I, Ohse T, Son D, Tawakami T, Yatagawa T, Inagi R, Fujita T, Nangaku M: Hypoxia and expression of hypoxia-inducible factor in the aging kidney. J Gerontol A Biol Sci Med Sci 2006; 61: 795-805.
28. Lam SY, Liu Y, Ng KM, Lau CF, Liong EC, Tipoe GL, Fung ML: Chronic intermittent hypoxia induces local inflammation of the rat carotid body via functional upregulation of proinflammatory cytokine pathways. Histochem Cell Biol 2012; 137: 303-317.
29. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J: TNF-alpha: A link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12: 454-461.
30. Pitsiou G, Kyriazis G, Hatzizisi O, Argyropoulou P, Mavrofridis E, Patakas D: Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med 2002; 96: 594-598.
31. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J: International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284.
32. Doria A, Niewczas MA, Fiorina P: Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol 2012; 32: 437-444.
33. Elmarakby AA, Quigley JE, Pollock DM, Imig JD: Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 2006; 47: 557-562.
34. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC: Immunosuppressive treatment protects against angiotensin ii-induced renal damage. Am J Pathol 2002; 161: 1679-1693.
35. Moriwaki Y, Inokuchi T, Yamamoto A, Ka T, Tsutsumi Z, Takahashi S, Yamamoto T: Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 2007; 44: 215-218.
36. Cho SK, Sung YK, Park S, Bae SC: Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis. Rheumatol Int 2010; 30: 1519-1522.